Diclofenac mouthwash as a potential therapy for reducing pain and discomfort in chemo-radiotherapy-induced oral mucositis

Página do item simplificado
dc.creatorPeter Brennan
dc.creatorPoornima Sakthithasan
dc.creatorSharon Mcguigan
dc.creatorOliver Donnelly
dc.creatorPeyman Alam
dc.creatorRicardo Santiago Gomez
dc.creatorStefano Fedele
dc.date.accessioned2024-11-26T21:53:55Z
dc.date.accessioned2025-09-09T00:32:37Z
dc.date.available2024-11-26T21:53:55Z
dc.date.issued2020
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1111/jop.13001
dc.identifier.issn1600-0714
dc.identifier.urihttps://hdl.handle.net/1843/78300
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofJournal of Oral Pathology & Medicine
dc.rightsAcesso Restrito
dc.subjectDiclofenac
dc.subjectStomatitis
dc.subjectPilot projects
dc.subjectRadiotherapy
dc.subjectMouthwashes
dc.subjectConsolidation chemotherapy
dc.subjectBenzydamine
dc.subjectPain
dc.subjectSquamous cell carcinoma of head and neck
dc.subject.otherDiclofenac
dc.subject.otherMouthwash
dc.subject.otheroral mucositis
dc.subject.otherPilot study
dc.subject.otherRadiotherapy
dc.titleDiclofenac mouthwash as a potential therapy for reducing pain and discomfort in chemo-radiotherapy-induced oral mucositis
dc.typeArtigo de periódico
local.citation.epage959
local.citation.issue9
local.citation.spage956
local.citation.volume49
local.description.resumoAims: Oral and/or oropharyngeal acute mucositis during and after chemo-radiotherapy (chemo-RT) for head and neck squamous cell carcinoma (HNSCC) can be extremely painful, sometimes requiring nasogastric feeding to enable adequate nutrition. The MASCC/ISOO evidence-based guidelines recommend benzydamine mouthwash for mucositis prevention in RT (recently updated to include chemo-RT), and a Cochrane systematic review found other agents to be effective in prophylaxis. Diclofenac mouthwash is licensed for painful oral mucosal inflammatory conditions but to our knowledge has not been assessed in chemo-RT-associated oral mucositis. Method: A clinical observation and service evaluation study in 10 patients undergoing chemo-RT for HNSCC to assess the potential value of diclofenac mouthwash (0.74 mg/mL) in reducing symptoms. Patients used 20ml of mouthwash up to 4 times a day starting in week 3 (of a 6-week course of treatment), recording pain and discomfort scores using a visual analogue scale on days 0, 1,7 and 14 (until the end of week 4). As per our current clinical practice, oral mucositis was not clinically scored as an outcome. Statistical analysis was performed using a one-way ANOVA. Results: Using diclofenac mouthwash, 9/10 patients experienced pain score reduction from day 0 (mean score 6.75 ± SD 1.83) to day 2 (5.05 ± SD 1.62) and day 14 (4.09 ± SD 1.96). Conclusions: Diclofenac mouthwash may be beneficial for managing chemo-RT-induced oral mucositis. While a prospective randomised clinical trial is needed, it can be prescribed for this condition within its current licence.
local.identifier.orcidhttps://orcid.org/0000-0003-4804-3264
local.identifier.orcidhttps://orcid.org/0000-0001-5710-9857
local.identifier.orcidhttps://orcid.org/0000-0001-8613-6686
local.identifier.orcidhttps://orcid.org/0009-0001-0616-3332
local.identifier.orcidhttps://orcid.org/0000-0001-8770-8009
local.identifier.orcidhttps://orcid.org/0000-0001-9006-9412
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICA
local.publisher.initialsUFMG
local.url.externahttps://onlinelibrary.wiley.com/doi/10.1111/jop.13001

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG